Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Roof who wrote (1003)	6/9/1998 11:47:00 PM
From: Todd D. Wiener	Read Replies (1) \| Respond to of 1432

It appears that Assensio's mislabeling of Nasdaq companies as OTC:BB stocks continues. Today, he went to work on CCSI, referring to it as a BB stock. I don't know if his statements about CCSI are true, but it seems that an honest report shouldn't need dishonest tidbits to be effective. However, Assensio seems to be comfortable having little integrity, so long as he makes money in the process. Todd

To: Jim Roof who wrote (1003)	6/10/1998 2:17:00 AM
From: Stephen How	Respond to of 1432

Jim, I tried to get a hold of the April 29 Crossen report. I had some problems, but Mesaone faxed me the report today. I'll look it over, but I suppose it says just what she posted ( www3.techstocks.com ). The Biotime press releases didn't specify the numbers that Crossen gave (transfusion patients (59% of study) losing an average of 1 L less blood in the Hextend&reg group with a p<.03). The wording never seemed that convincing (you paraphased "very happy" and "significantly"). I suppose I'll assume that Crossen is telling the truth, and that the numbers he presents shows a "significant" improvement over hetastarch :). I'll check the wording of Crossen's recommendation tomorrow. I'll probably calm down, and not post much anymore. This is becoming too much of an obsession. I'll keep the web page up, and maybe just post there. I want the stock price to go up anyway. Of course it would have been a lot better if the Puerto Rico posters, or some other press release or published study would have presented this favorbale blood loss analysis. Otherwise, we just have to take Crossen's word for it. He wasn't involved in the study, and the neither the company nor the researchers presented this data. Oh well. I'm not convinced, but I'll be quieter from now. Steve btim.dyn.ml.org